Activated PI3K and RTK signaling and response/resistance to HER2 targeted therapy

被引：0
|
作者：
O'Brien, Neil
Browne, Brigid
Chow, Lucy
Ginther, Charles
Bensadigh, Brian
Atefi, Mohammad
Arboleda, Jane
Duffy, Michael
Crown, John
O'Donovan, Norma
Slamon, Dennis
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Natl Inst Cellular Biotechnol, Dublin, Ireland
[3] Conway Inst, UCD Sch Med & Med Sci, Dublin, Ireland
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
765
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination
    Balz, Lydia M.
    Bartkowiak, Kai
    Andreas, Antje
    Pantel, Klaus
    Niggemann, Bernd
    Zaenker, Kurt S.
    Brandt, Burkhard H.
    Dittmar, Thomas
    JOURNAL OF PATHOLOGY, 2012, 227 (02): : 234 - 244
  • [32] Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy
    Wani, Atif Khurshid
    Singh, Reena
    Akhtar, Nahid
    Prakash, Ajit
    Nepovimova, Eugenie
    Oleksak, Patrik
    Chrienova, Zofia
    Alomar, Suliman
    Chopra, Chirag
    Kuca, Kamil
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (16) : 1496 - 1520
  • [33] PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
    Zhang, Hongyan
    Zhang, Longlong
    He, Yuna
    Jiang, Dewei
    Sun, Jian
    Luo, Qianmei
    Liang, Huichun
    Wang, Tiantian
    Li, Fubing
    Tang, Yu
    Yang, Zimo
    Liu, Wenjing
    Rao, Yu
    Chen, Ceshi
    CANCER LETTERS, 2024, 598
  • [34] Growth Suppression of HER2-Overexpressing Breast Cancer Cells by Berberine via Modulation of the HER2/PI3K/Akt Signaling Pathway
    Kuo, Han-Peng
    Chuang, Tzu-Chao
    Yeh, Ming-Han
    Hsu, Shih-Chung
    Way, Tzong-Der
    Chen, Po-Yuan
    Wang, Shan-Shue
    Chang, Yung-Hsien
    Kao, Ming-Ching
    Liu, Jah-Yao
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2011, 59 (15) : 8216 - 8224
  • [35] Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
    Mezynski, M. Janusz
    Farrelly, Angela M.
    Cremona, Mattia
    Carr, Aoife
    Morgan, Clare
    Workman, Julie
    Armstrong, Paul
    McAuley, Jennifer
    Madden, Stephen
    Fay, Joanna
    Sheehan, Katherine M.
    Kay, Elaine W.
    Holohan, Ciara
    Elamin, Yasir
    Rafee, Shereen
    Morris, Patrick G.
    Breathnach, Oscar
    Grogan, Liam
    Hennessy, Bryan T.
    Toomey, Sinead
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [36] Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
    M. Janusz Mezynski
    Angela M. Farrelly
    Mattia Cremona
    Aoife Carr
    Clare Morgan
    Julie Workman
    Paul Armstrong
    Jennifer McAuley
    Stephen Madden
    Joanna Fay
    Katherine M. Sheehan
    Elaine W. Kay
    Ciara Holohan
    Yasir Elamin
    Shereen Rafee
    Patrick G. Morris
    Oscar Breathnach
    Liam Grogan
    Bryan T. Hennessy
    Sinead Toomey
    Journal of Translational Medicine, 19
  • [37] Notch signaling regulates recurrence in a model of HER2 targeted therapy
    Abravanel, Daniel L.
    Sterner, Christopher J.
    Pan, Tien-chi
    Belka, George K.
    Chodosh, Lewis A.
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [38] HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway:: An unexpected effect on TRAIL-induced apoptosis
    Dubská, L
    Andera, L
    Sheard, MA
    FEBS LETTERS, 2005, 579 (19) : 4149 - 4158
  • [39] MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers
    Hoe, Nicholas
    Mateling, Michael
    Ma, Yating
    Jin, Kelly
    Zhou, JinYao
    Kirkland, Richard
    Kuy, Crystal
    Liu, Xinjun
    Kim, Phillip
    Singh, Sharat
    CANCER RESEARCH, 2013, 73 (08)
  • [40] Her2 a paradigm for targeted therapy
    Marijon, Helene
    Andre, Fabrice
    BULLETIN DU CANCER, 2011, 98 (09) : 1011 - 1017
12345